Gyre Therapeutics (GYRE) EBITDA Margin (2010 - 2026)
Gyre Therapeutics (GYRE) reported EBITDA Margin of 41.54% for Q1 2026, down 5185.0% year-over-year from 0.82% in Q1 2025, and down 85.34% quarter-over-quarter from 22.41% in Q4 2025.
Gyre Therapeutics (GYRE) EBITDA Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 16 years of EBITDA Margin data on file, last reported at 41.54% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 41.54%, down 5185.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 7.34% (down 1764.0% YoY), and the FY2025 annual result was 2.6%, down 1268.0% from the prior year.
- EBITDA Margin slipped to 41.54% in Q1 2026 per GYRE's latest filing, from 22.41% in the prior quarter.
- Over five years, EBITDA Margin peaked at 39.84% in Q3 2023 and troughed at 1851.51% in Q1 2022.
- A 5-year average of 139.28% and a median of 10.3% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin sank 32200 bps in 2022, then soared 187824 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 22.13% in 2022, then sank by 1425 bps to 337.53% in 2023, then soared by 101 bps to 2.39% in 2024, then plunged by 1039 bps to 22.41% in 2025, then tumbled by 85 bps to 41.54% in 2026.
- Business Quant data shows GYRE's EBITDA Margin at 41.54% in Q1 2026, 22.41% in Q4 2025, and 22.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -41.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.54% |
| Dec 31, 2025 | -22.41% |
| Sep 30, 2025 | 22.66% |
| Jun 30, 2025 | 8.11% |
| Mar 31, 2025 | 10.30% |
| Dec 31, 2024 | 2.39% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 12.66% |
| Mar 31, 2024 | 29.70% |
| Dec 31, 2023 | -337.53% |
| Sep 30, 2023 | 39.84% |
| Jun 30, 2023 | 16.96% |
| Mar 31, 2023 | 26.73% |
| Dec 31, 2022 | -22.13% |
| Mar 31, 2022 | -1,851.51% |
| Dec 31, 2021 | -832.50% |
| Sep 30, 2021 | -1,097.39% |
| Jun 30, 2021 | -1,759.19% |
| Mar 31, 2021 | -1,529.52% |
| Dec 31, 2020 | -927.67% |